News · Heart & Metabolic
Weight-loss surgery cost less downstream than the drugs
A JAMA Network Open study matched 2,721 pairs of Israeli patients over up to 12.5 years and found those on GLP-1 drugs ran up $109 more per month in other health costs than surgery patients.
Based on a peer-reviewed cohort study in JAMA Network Open
- Researchers used records from Clalit Health Services, Israel's largest health organization, publishing in JAMA Network Open.
- Adults with obesity and diabetes who started GLP-1 drugs or had bariatric surgery between 2010 and 2022 were propensity matched into 2,721 pairs, 5,442 people, followed a mean 6.5 years and up to 12.5.
- Monthly downstream costs averaged $415.30 for GLP-1 patients against $304.90 for surgery patients.
- Adjusted, that is $109.00 more per month per patient on GLP-1 drugs, driven by hospitalization ($43.90) and non-GLP-1 medications ($52.50).
- Most of the difference accrued in the first four years, then flattened.
- Surgery produced greater early falls in BMI and blood sugar; the drugs gave more modest but sustained effects.
- Critically, these figures EXCLUDE the cost of the interventions themselves. This is about what happens afterwards, not total cost.
- Observational and Israeli. Matching balances measured factors, not the reasons a patient and doctor chose one route.
The arrival of effective weight-loss drugs was supposed to make bariatric surgery look like a relic. A study in JAMA Network Open, published by the American Medical Association, followed both groups for up to twelve and a half years and found the operation ahead on one measure nobody markets.
Among 5,442 matched adults with obesity and diabetes, mean monthly follow-up costs were higher among patients treated with GLP-1 drugs than those who underwent surgery.
Why the question is now worth asking
Both approaches work. As the authors put it, bariatric metabolic surgery and glucagon-like peptide-1 receptor agonists are effective interventions, but their long-term impact on health care utilization costs remains incompletely understood.
Until now that question was hard to answer, because it needs a decade of records on people who chose each route. Israel’s unified health system supplies exactly that.
How the comparison was built
The study used electronic medical records from Clalit Health Services, the largest health care organization in Israel, covering adults with obesity and diabetes who had their first surgery or started GLP-1 therapy between January 2010 and December 2022.
Propensity score matching yielded 2721 matched pairs, who were followed up for up to 12.5 years, mean 6.5 years. The matched cohort included 5442 adults, mean age 51 years, 3243 women (59.6%), and mean body mass index of 40.5.
The outcome was health care utilization costs incurred by the health system, excluding costs of the index interventions. That exclusion is the single most important thing to hold in mind.
The gap, and where it came from
Mean monthly follow-up costs were $415.30 among GLP-1 patients against $304.90 among surgery patients.
Adjusted, the difference showed $109.0 higher monthly costs per patient for GLP-1 treatment, associated primarily with hospitalization costs at $43.90 and non-GLP-1 medication costs at $52.50.
Most cost differences accrued within the first 4 years, after which the curves ran closer together.
The clinical pattern underneath
The costs track a difference in how the two treatments behave. Surgery was associated with greater early reductions in body mass index and blood sugar, whereas GLP-1 treatment showed more modest but sustained effects.
A sharper early metabolic correction plausibly means fewer complications and less additional medication over the following years. The study documents the association; it does not prove that chain.
What this is not
It is not a total cost comparison. Neither the price of an operation nor the recurring price of a GLP-1 prescription appears in these figures, and those are the two largest numbers in the whole question. Given the drugs are an indefinite monthly cost and surgery is mostly one-off, including them would probably widen the gap, but that is inference rather than finding.
It is also observational. Matching balances what was recorded; it cannot balance why a particular patient and doctor chose surgery over a prescription.
And the prices are Israeli. The clinical direction may generalize; the dollars will not.
The authors’ conclusion sticks to the system’s perspective: among patients eligible for both interventions, surgery may confer combined clinical and economic advantages over long-term follow-up.
For an individual weighing the two, that is one consideration sitting alongside operative risk, reversibility and whether they can stay on a drug for the rest of their life.
People also ask
Does this mean surgery is cheaper overall?
Not established, and the exclusion is the reason. The analysis measured health care utilization costs excluding costs of the index interventions, so neither the price of the operation nor the ongoing price of the drugs is in these numbers. Since GLP-1 drugs are an indefinite monthly expense and surgery is largely one-off, including both would likely widen the gap rather than close it, but this study did not do that arithmetic.
Why would drug patients cost more downstream?
The two largest components were hospitalization at $43.90 per month and non-GLP-1 medication at $52.50. The researchers link this to differences in early clinical trajectories: surgery produced greater early reductions in body mass index and blood sugar, which plausibly means fewer complications and less other medication in the following years. That is an interpretation of the pattern, not something the study proved.
Is this a fair comparison?
It is a careful one, with limits. Propensity score matching pairs patients who look similar on measured characteristics, but people who choose surgery differ from those who choose drugs in motivation, severity and clinician judgement in ways records do not capture. This is the standing weakness of comparing two treatments nobody was randomized to.
Does it apply outside Israel?
Partly. The clinical pattern, where surgery produces larger early metabolic change, is consistent with trial evidence elsewhere. The cost figures are specific to one national system with its own prices, prescribing rules and hospital tariffs. The direction may travel; the dollar amounts will not.
Should this change what someone chooses?
It is one input among several, and this is general information rather than advice. Surgery carries operative risk, is irreversible and is not suitable for everyone; drugs are reversible but require indefinite adherence and lose their effect when stopped. Cost to a health system is a different question from what is right for one patient. That conversation belongs with a clinician.